A promising meta-analysis of eleven placebo-controlled or active-controlled phase-2 RCTs demonstrated that treatment with GLP1-RAs (exenatide, semaglutide, liraglutide, dulaglutide) in patients with MASLD was correlated with a reduction in serum liver enzyme levels and an absolute percentage of liver fat content on magnetic resonance-based techniques and a histological resolution of MASH without worsening of liver fibrosis. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.